Investing in Psychedelics with Entheon Biomedical | Presented by CSE and CFN Media

Presented as part of the CSE and CFN Media's exclusive video series on Investing in Psychedelics. This interview with Entheon Biomedical CEO Timothy Ko highlights his plans to commercialize a portfolio of safe and effective psychedelic therapies specifically designed to treat addiction disorders. Entheon Biomedical works alongside a growing community of scientists and medical professionals to dispel and overcome the misconceptions about the clinical use of psychedelics.

Subscribe to CSE TV to learn more about up-and-coming public and private sector companies paving the way for the psychedelics industry with innovative applications. This series will also feature brokerage and banking experts discussing investment opportunities and due diligence in the psychedelics market.